Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Leases: 2021-2025

Historic Current Leases for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.7 million.

  • Krystal Biotech's Current Leases rose 31.42% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 31.42%. This contributed to the annual value of $1.2 million for FY2024, which is 17.44% down from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Current Leases is $1.7 million, which was up 5.01% from $1.6 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Current Leases high stood at $1.7 million for Q3 2025, and its period low was $648,000 during Q1 2021.
  • In the last 3 years, Krystal Biotech's Current Leases had a median value of $1.5 million in 2023 and averaged $1.5 million.
  • As far as peak fluctuations go, Krystal Biotech's Current Leases surged by 117.75% in 2022, and later decreased by 17.44% in 2024.
  • Over the past 5 years, Krystal Biotech's Current Leases (Quarterly) stood at $1.0 million in 2021, then skyrocketed by 49.95% to $1.6 million in 2022, then decreased by 5.57% to $1.5 million in 2023, then declined by 17.44% to $1.2 million in 2024, then skyrocketed by 31.42% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.6 million for Q2 2025, and $1.4 million during Q1 2025.